Literature DB >> 31306757

Epidemiologic and survival trends in adult primary bone tumors of the spine.

David L Kerr1, Brian L Dial2, Alexander L Lazarides1, Anthony A Catanzano1, Whitney O Lane3, Dan G Blazer3, Brian E Brigman1, Sergio Mendoza-Lattes1, William C Eward1, Melissa E Erickson1.   

Abstract

BACKGROUND CONTEXT: Malignant primary spinal tumors are rare making it difficult to perform large studies comparing epidemiologic, survival, and treatment trends. We investigated the largest registry of primary bone tumors, the National Cancer Database (NCDB), to compare epidemiologic and survival trends among these tumors.
PURPOSE: To use the NCDB to describe current epidemiologic trends, treatment modalities, and overall survival rates in patients with chordomas, osteosarcomas, chondrosarcomas, and Ewing sarcomas of the mobile spine. The secondary objective was to determine prognostic factors that impact overall survival rates. STUDY
DESIGN: Retrospective study. PATIENT SAMPLE: A total of 1,011 patients with primary bone tumors of the spine (377 chordomas, 223 chondrosarcomas, 278 Ewing sarcomas, and 133 osteosarcomas). OUTCOME MEASURES: Five-year survival.
METHODS: We reviewed the records of 1,011 patients in the NCDB from 2004 through 2015 with histologically confirmed primary osteosarcoma, chondrosarcoma, Ewing sarcoma, or chordoma of the spine. Demographic, clinical, and outcomes data were compiled and compared using chi-squared tests and ANOVA. Long-term survival was compared using the Kaplan-Meier method with statistical comparisons based on the log-rank test. Multivariate analysis was performed to determine survival determinants.
RESULTS: Surgical resection was the primary mode of treatment for chondrosarcoma (90%), chordoma (84%), and osteosarcoma (80%). The treatment for Ewing sarcoma was multimodal involving chemotherapy, radiation therapy, and surgical resection. Five-year survival rates varied significantly with chordomas and chondrosarcomas having the greatest survival (70% and 69%), osteosarcomas having the worse survival (38%), and Ewing having intermediate 5-year survival at 62% (overall log-rank p<.0001). Multivariate analysis demonstrated significantly improved 5-year survival rates with younger age at diagnosis, private insurance status, lower comorbidity score, lower tumor grade, smaller tumor size, surgical resection, and negative surgical margin. Radiation therapy only improved survival for Ewing sarcoma.
CONCLUSIONS: This study provides the most comprehensive description of the epidemiologic, treatment, and survival trends of primary bone tumors of the mobile spine. Second, patient and tumor characteristics associated with improved 5-year survival were identified using a multivariate model.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chondrosarcoma; Chordoma; Ewing sarcoma; National Cancer Database; Osteosarcoma; Spinal tumors; Survival

Mesh:

Year:  2019        PMID: 31306757     DOI: 10.1016/j.spinee.2019.07.003

Source DB:  PubMed          Journal:  Spine J        ISSN: 1529-9430            Impact factor:   4.166


  10 in total

1.  Construction of a Diagnostic Model for Distinguishing Benign or Malignant Bone Cancer by Mining miRNA Expression Data.

Authors:  Yueming Zhang; Jianwei Hu; Tao Li; Shizhu Hao; Xiaotang Wu
Journal:  Biochem Genet       Date:  2022-07-21       Impact factor: 2.220

2.  Epidemiologic trend of mobile spine and sacrum chordoma: A National population-based study.

Authors:  Mohammadreza Chehrassan; Adel Ebrahimpour; Mehrdad Sadighi; Mehdi Azizmohammad Looha; Saber Barazandeh Rad; Mohammad Esmaeil Akbari
Journal:  J Craniovertebr Junction Spine       Date:  2020-08-14

3.  Pathological Clinical Analysis and Imaging Manifestations for Spinal Bone Tumors Based on Cement Injection.

Authors:  Jie Li; Xu Wang; Yongmin Li; Qinhui Cao; Yi Bu; Hengcong Cao; Xiaoqiang Wang
Journal:  Appl Bionics Biomech       Date:  2022-04-25       Impact factor: 1.664

4.  Upper cervical spine reconstruction using customized 3D-printed vertebral body in 9 patients with primary tumors involving C2.

Authors:  Feng Wei; Zhehuang Li; Zhongjun Liu; Xiaoguang Liu; Liang Jiang; Miao Yu; Nanfang Xu; Fengliang Wu; Lei Dang; Hua Zhou; Zihe Li; Hong Cai
Journal:  Ann Transl Med       Date:  2020-03

5.  Primary Ewing sarcoma/peripheral primitive neuroectodermal tumors in the cranial bone and mobile spine: what is the difference?

Authors:  Yu Wang; Hui Zhang; Jun Chen; Shi-Zhou Wu; Jie Tan; Qing-Yi Zhang; Bo-Quan Qin
Journal:  BMC Surg       Date:  2022-01-08       Impact factor: 2.102

Review 6.  Recent Advances in the Treatment of Bone Metastases and Primary Bone Tumors: An Up-to-Date Review.

Authors:  Adrian Emilian Bădilă; Dragoș Mihai Rădulescu; Adelina-Gabriela Niculescu; Alexandru Mihai Grumezescu; Marius Rădulescu; Adrian Radu Rădulescu
Journal:  Cancers (Basel)       Date:  2021-08-23       Impact factor: 6.639

7.  Proton Therapy for Primary Bone Malignancy of the Pelvic and Lumbar Region - Data From the Prospective Registries ProReg and KiProReg.

Authors:  Rasin Worawongsakul; Theresa Steinmeier; Yi-Lan Lin; Sebastian Bauer; Jendrik Hardes; Stefanie Hecker-Nolting; Uta Dirksen; Beate Timmermann
Journal:  Front Oncol       Date:  2022-02-16       Impact factor: 6.244

8.  Individualized assessment of risk and overall survival in patients newly diagnosed with primary osseous spinal neoplasms with synchronous distant metastasis.

Authors:  Yuexin Tong; Zhangheng Huang; Liming Jiang; Yangwei Pi; Yan Gong; Dongxu Zhao
Journal:  Front Public Health       Date:  2022-08-22

9.  [An application of posterior cervical and transoral approaches to treating primary malignant osseous tumors in craniovertebral junction].

Authors:  Yu Zhang; Fuzhi Ai; Suochao Fu; Keke Li; Hong Xia; Zenghui Wu; Xiangyang Ma
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2020-09-15

10.  Has the Affordable Care Act Been Associated with Increased Insurance Coverage and Early-stage Diagnoses of Bone and Soft-tissue Sarcomas in Adults?

Authors:  Azeem Tariq Malik; John Alexander; Safdar N Khan; Thomas J Scharschmidt
Journal:  Clin Orthop Relat Res       Date:  2021-03-01       Impact factor: 4.755

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.